Literature DB >> 1696342

Surface co-expression of Vibrio cholerae and Salmonella typhi O-antigens on Ty21a clone EX210.

S R Attridge1, D Daniels, J K Morona, R Morona.   

Abstract

In an attempt to construct a bivalent, live, oral cholera-typhoid vaccine, genes specifying the biosynthesis of Vibrio cholerae O-antigen have been transferred into a modified version of the attenuated, oral typhoid vaccine strain Salmonella typhi Ty21a. The present report investigates the production of V. cholerae and S. typhi O-antigens by one such clone, EX210. When cultured without galactose supplementation EX210 produces surface O-antigen of V. cholerae type, as detected by haemagglutination-inhibition and bactericidal assays, and by immuno-electron microscopy. However, the protective efficacy of Ty21a depends upon growth in the presence of exogenous galactose and under these conditions only S. typhi O-antigen is detectable on the surface of EX210. Subsequent experiments revealed that the proportion of polysaccharide of S. typhi type is dependent upon the level of galactose supplementation, and identified a limiting sugar concentration which results in surface co-expression of both O-antigens. Visualization of the two polysaccharides on silver-stained polyacrylamide gels indicates that S. typhi O-antigen subunits are polymerized into longer sidechains, suggesting that at higher galactose concentrations their predominance results in a masking of the shorter V. cholerae O-antigen.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696342     DOI: 10.1016/0882-4010(90)90045-r

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  9 in total

Review 1.  Recombinant avirulent salmonellae as oral vaccine carriers.

Authors:  F Schödel
Journal:  Infection       Date:  1992 Jan-Feb       Impact factor: 3.553

2.  Construction and characterization of a live attenuated vaccine candidate against Shigella dysenteriae type 1.

Authors:  S R Klee; B D Tzschaschel; I Fält; A Kärnell; A A Lindberg; K N Timmis; C A Guzmán
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

3.  A biologically conjugated polysaccharide vaccine delivered by attenuated Salmonella Typhimurium provides protection against challenge of avian pathogenic Escherichia coli O1 infection.

Authors:  Yue Han; Qing Liu; Jie Yi; Kang Liang; Yunan Wei; Qingke Kong
Journal:  Pathog Dis       Date:  2017-11-30       Impact factor: 3.166

4.  Susceptibility of Vibrio cholerae O139 to antibody-dependent, complement-mediated bacteriolysis.

Authors:  S R Attridge; F Qadri; M J Albert; P A Manning
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

5.  Characterization and immunogenicity of EX880, a Salmonella typhi Ty21a-based clone which produces Vibrio cholerae O antigen.

Authors:  S R Attridge; C Dearlove; L Beyer; L van den Bosch; A Howles; J Hackett; R Morona; J LaBrooy; D Rowley
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

6.  Influence of different rol gene products on the chain length of Shigella dysenteriae type 1 lipopolysaccharide O antigen expressed by Shigella flexneri carrier strains.

Authors:  S R Klee; B D Tzschaschel; K N Timmis; C A Guzman
Journal:  J Bacteriol       Date:  1997-04       Impact factor: 3.490

7.  Immunogenicity of Salmonella typhi Ty21a vaccine for young children.

Authors:  J R Murphy; L Grez; L Schlesinger; C Ferreccio; S Baqar; C Muñoz; S S Wasserman; G Losonsky; J G Olson; M M Levine
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

8.  Development of Shigella sonnei live oral vaccines based on defined rfbInaba deletion mutants of Vibrio cholerae expressing the Shigella serotype D O polysaccharide.

Authors:  D Favre; S J Cryz; J F Viret
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

9.  Molecular, genetic, and topological characterization of O-antigen chain length regulation in Shigella flexneri.

Authors:  R Morona; L van den Bosch; P A Manning
Journal:  J Bacteriol       Date:  1995-02       Impact factor: 3.490

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.